4DN Stock Overview
A biopharmaceutical company, develops a portfolio of product candidates engineered to cross the blood-brain barrier for neurodegenerative diseases and lysosomal storage diseases in the United States. More details
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
Denali Therapeutics Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$23.67 |
| 52 Week High | US$29.67 |
| 52 Week Low | US$13.94 |
| Beta | 1.39 |
| 11 Month Change | -6.29% |
| 3 Month Change | 8.03% |
| 1 Year Change | 43.45% |
| 33 Year Change | -39.63% |
| 5 Year Change | 44.08% |
| Change since IPO | 61.35% |
Recent News & Updates
Recent updates
Shareholder Returns
| 4DN | DE Biotechs | DE Market | |
|---|---|---|---|
| 7D | 3.3% | 1.2% | 0.9% |
| 1Y | 43.5% | -19.2% | 7.7% |
Return vs Industry: 4DN exceeded the German Biotechs industry which returned -18.5% over the past year.
Return vs Market: 4DN exceeded the German Market which returned 7.9% over the past year.
Price Volatility
| 4DN volatility | |
|---|---|
| 4DN Average Weekly Movement | 8.0% |
| Biotechs Industry Average Movement | 6.7% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in DE Market | 11.3% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: 4DN's share price has been volatile over the past 3 months compared to the German market.
Volatility Over Time: 4DN's weekly volatility (8%) has been stable over the past year, but is still higher than 75% of German stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2013 | 390 | Ryan Watts | www.denalitherapeutics.com |
Denali Therapeutics Inc., a biopharmaceutical company, develops a portfolio of product candidates engineered to cross the blood-brain barrier for neurodegenerative diseases and lysosomal storage diseases in the United States. The company’s transport vehicle (TV)-enabled programs include DNL310 ETV, an IDS enzyme replacement therapy program for MPS II; TAK-594/DNL593 which is in Phase 1/II for frontotemporal dementia-granulin; DNL126 program for MPS IIIA; and DNL622 for MPS I, as well as other preclinical programs that target amyloid beta and HER2. Its brain-penetrant small molecule programs comprise BIIB122/DNL151 LRRK2 inhibitor program for Parkinson's disease; SAR443820/DNL788 RIPK1 inhibitor program for CNS disease; DNL343 eIF2B Activator program for amyotrophic lateral sclerosis; and SAR443122/DNL758 RIPK1 inhibitor program for peripheral inflammatory diseases.
Denali Therapeutics Inc. Fundamentals Summary
| 4DN fundamental statistics | |
|---|---|
| Market cap | €3.40b |
| Earnings (TTM) | -€403.98m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-8.4x
P/E RatioIs 4DN overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 4DN income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$412.36m |
| Gross Profit | -US$412.36m |
| Other Expenses | US$15.14m |
| Earnings | -US$427.49m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -2.97 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0% |
How did 4DN perform over the long term?
See historical performance and comparison